文献速递中医内科中药与中成药合理使用

中药治疗轻度认知障碍:随机安慰剂对照试验的系统评价与Meta分析

The efficacy and safety of Chinese herbal medicine for mild cognitive impairment: a systematic review and meta-analysis of randomized placebo-controlled trials.
PubMed 文献 · Front Pharmacol · 2024-02-15

该系统评价纳入13项随机安慰剂对照试验共1043例轻度认知障碍患者,评估口服中药的疗效与安全性。

要点

  • 中药可改善MCI患者MMSE和MoCA评分,证据确定性中至低。
  • 不良事件以胃肠道症状最常见,组间无显著差异。
  • 部分研究未报告或未详细报告不良事件,安全性需谨慎解读。

核心结论

  • 中药可能有效改善MCI患者的认知功能,证据确定性为低至中度。
  • 现有数据提示中药总体安全,但部分研究缺乏不良事件报告或详细信息,需谨慎。

研究设计与样本

  • 系统评价与Meta分析,检索9个数据库至2023年1月,纳入口服中药治疗MCI的随机安慰剂对照试验。
  • 共纳入13项研究,涉及1043名参与者;采用Cochrane风险偏倚工具2.0评估质量,GRADE评估证据确定性。

主要发现

  • 与安慰剂相比,中药显著改善MMSE评分(MD 1.90 [1.22, 2.58],I2=87%,11项研究,823名参与者)。
  • 与安慰剂相比,中药显著改善MoCA评分(MD 2.88 [1.69, 4.06],I2=81%,3项研究,241名参与者)。
  • 不良事件组间无显著差异(RR 1.31 [0.92, 1.87),I2=0%,11项研究,839名参与者)。
  • 13项研究中10项总体风险偏倚为「some concerns」。
  • 常用中药(人参、石菖蒲、远志)的认知增强作用可能归因于抗氧化、抗凋亡、抗神经毒性、抗细胞毒和抗炎机制。

关键数值与推荐

  • 1项研究未报告不良事件,1项报告组间无统计学差异,11项提供不良事件详细例数。
  • 2项研究报告无严重不良事件,1项发现组间严重不良事件比例无显著差异。

临床怎么用

  • 可考虑将中药作为MCI患者改善认知功能的潜在干预选项。
  • 使用中药时需关注胃肠道不良事件,并注意部分研究缺乏不良事件详细报告。
  • 临床决策应结合证据确定性(低至中度)及患者个体情况。

局限性

  • 多数研究(10/13)存在「some concerns」的总体风险偏倚。
  • MMSE和MoCA分析的异质性较高(I2分别为87%和81%)。
  • 部分研究未报告或未详细报告不良事件,安全性数据不完整。
  • MoCA的证据确定性为「low」。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Effective and safe treatments for mild cognitive impairment (MCI) are limited. Chinese herbal medicine (CHM) is commonly used in China to manage MCI. However, its efficacy and safety remain uncertain. This review aims to evaluate the efficacy and safety of CHM for MCI. Methods: Nine databases were searched from their inceptions to January 2023. Randomized, placebo-controlled trials of oral CHM for MCI were included. Study quality was assessed using the Cochrane risk-of-bias tool 2.0, and the certainty of evidence was evaluated via the GRADE approach. Results: Thirteen studies, involving 1,043 participants, were analyzed. Most of the studies (10 out of 13) were associated with "some concerns" regarding the overall risk of bias. Meta-analyses results indicated that CHM significantly improved cognitive function compared to placebo in terms of Mini-Mental State Examination (MMSE) (MD: 1.90 [1.22, 2.58], I2 = 87%, 11 studies, 823 participants) and Montreal Cognitive Assessment (MoCA) (MD: 2.88 [1.69, 4.06], I2 = 81%, 3 studies, 241 participants). The certainty of evidence for MMSE was assessed as "moderate", while it was "low" for MoCA. One study did not report adverse events (AEs), one study reported no statistical difference between the groups in terms of AEs, and 11 studies provided detailed numbers of AE cases where gastrointestinal symptoms were the most commonly reported AEs. Two studies reported no SAEs among participants and one study found no significant difference in SAEs proportions between groups. The meta-analysis revealed no significant difference in AEs between the two groups (RR: 1.31 [0.92, 1.87), I2 = 0%, 11 studies, 839 participants). The cognitive-enhancing function of commonly used herbs (Panax ginseng C.A.Mey., Acorus calamus var. angustatus Besser, and Polygala tenuifolia Willd.) may be attributed to mechanisms including antioxidant, anti-apoptotic, anti-neurotoxic, anti-cytotoxic, and anti-inflammatory actions. Conclusion: Chinese herbal medicine holds potential as an effective intervention to improve cognitive function in MCI patients, supported by meta-analyses evidence of low to moderate certainty. Although current data suggests CHM is generally safe, caution is advised due to the lack of AE reporting or detailed information in some instances. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=400292, identifier [CRD42023400292].

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu L, Zhang CS, Zhang AL, et al. The efficacy and safety of Chinese herbal medicine for mild cognitive impairment: a systematic review and meta-analysis of randomized placebo-controlled trials. Front Pharmacol. 2024. PMID: 38425647. doi:10.3389/fphar.2024.1341074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。